Heart failure & cardiomyopathiesCohort study
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and Type 2 diabetes: data from the Swedish Heart Failure Registry and National Diabetes Registry
- Registry-based cohort study
- linked national registries
Authors' conclusion
In HF, T2DM was associated with higher use of SGLT2i and lower use of MRA and RASi/ARNI despite being linked with a higher risk of death and HHF. In T2DM, presence of HF was linked with higher SGLT2i use and an independent higher risk of death and myocardial infarction. Heart failure was associated with comparatively greater risk increase than T2DM.
Study context
- Population
- Patients with Heart Failure (HF) and/or T2DM, Swedish HF Registry and National Diabetes Registry, 2017–2021HF cohort 37,903
- Exposure
- T2DM vs no T2DM in HF; HF vs no HF in T2DM
Main finding
As reported in the abstract
Treatment patterns and outcomes (HF cohort: T2DM vs no T2DM) · median follow-up 1.8 years
- T2DM associated with 10-fold higher SGLT2 inhibitor use
- T2DM associated with less likely MRA use irrespective of ejection fraction (EF), and of RAS inhibitors/ARNI in HF with reduced and mildly reduced EF
- T2DM associated with higher risk of first HF hospitalization/cardiovascular (CV) death, first HF hospitalization and all-cause death, but not CV death alone
- independently associated
Observational data: associations, not effects.
Original publication
Pharmacological treatment patterns and outcomes according to the coexistence of heart failure and Type 2 diabetes: data from the Swedish Heart Failure Registry and National Diabetes Registry. Eur J Prev Cardiol. Published 14 August 2025. doi:10.1093/eurjpc/zwaf504
Summarised from the published abstract; every number is checked against it